Clorox reported fiscal third‑quarter 2026 results that were largely in line with revenue expectations but included a modest earnings beat. Net sales totaled $1.67 billion, flat year‑over‑year, while organic sales slipped 1%. Gross margin fell 140 basis points to 43.2% from 44.6% a year earlier. GAAP diluted earnings per share rose 3% to $1.54, surpassing the consensus estimate of $1.48, and adjusted EPS climbed 13% to $1.64 from $1.45.
The earnings beat was driven by disciplined cost management amid a backdrop of higher manufacturing and logistics expenses. Although the company faced margin compression, it offset the impact through pricing power in its core household and international segments and by maintaining efficient inventory levels. The 140‑basis‑point decline in gross margin reflects the combined effect of raw‑material inflation, supply‑chain disruptions, and a shift toward lower‑margin product mixes, yet the company’s ability to keep earnings above expectations signals effective operational control.
Management lowered its full‑year guidance in response to several headwinds. Net sales are now expected to decline about 6%, a tighter outlook than the prior 6‑10% range, while organic sales are projected to fall 9% versus the earlier 5‑9% forecast. Diluted EPS guidance was cut to $4.78‑$4.98, a 24‑27% year‑over‑year drop, and adjusted EPS guidance was reduced to $5.45‑$5.65, a 27‑29% decline. The revisions stem from the ongoing ERP inventory normalization, integration costs from the April 1 acquisition of GOJO Industries, and persistent cost inflation.
Segment analysis shows that the Household and International divisions delivered solid growth, offsetting a decline in Lifestyle revenue. The company’s Fresh Step line, part of the Lifestyle segment, is undergoing a “complete reinvention” with new product names, claims, and price‑pack architecture, which is expected to take several years to fully materialize. The GOJO acquisition is projected to add roughly 3 percentage points to fiscal 2026 net sales but will dilute adjusted EPS by 2‑4 cents in the near term.
CEO Linda Rendle emphasized that the ERP implementation, while creating short‑term disruption, is laying the foundation for future growth. She noted that the company’s focus has shifted to regaining momentum, accelerating innovation to shelf, and sharpening execution. CFO Luc Bellet added that ERP‑related costs are expected to be minimal in the fourth quarter and that cost‑saving initiatives will continue to roll out into the next fiscal year.
Investors reacted with caution. Morgan Stanley reduced its price target to $97 from $110, reflecting the sharper guidance and the challenges posed by cost inflation and integration expenses. The market’s focus on the lowered outlook underscores the importance of forward‑looking metrics over the current quarter’s earnings beat.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.